Chagas Cardiomyopathy Clinical Trial
Official title:
Microvascular Endothelial Function in a Cohort of Patients With the Cardiac Form of Chronic Chagas Disease.
The present study aims to evaluate the microvascular endothelial function of a single centre cohort of patients with the cardiac form of Chagas disease, and to search for associations with clinical and laboratory variables.
Chagas disease is an endemic anthropozoonosis in South America, caused by the
protozoaTrypamosoma cruzi. Between 15 and 17 million people are estimated to be infected by
the parasite in South America. During the chronic phase, 30 to 40% of patients develop the
cardiac or intestinal forms of the disease. The myocardial involvement is divided in two
subtypes, according to the presence or absence of systolic ventricular dysfunction. The first
type is characterized by heart failure symptoms. The second is acknowledged by the
development of various degrees of atrioventricular blockade and by tachyarrhythmias.
Microcirculation function is recognized as a fundamental aspect in the pathophysiology of
cardiovascular diseases. The identification of endothelial dysfunction by techniques that
assess the microvasculature is considered as both a progression and prognostic marker in
various conditions, including hypertension, coronary heart disease, and heart failure.
The effects of T. cruzi infection in vascular function were evaluated in previous studies,
performed in animals with acute infection. Previous studies in humans observed medium size
vessels (brachial artery), in small groups of patients, most without cardiac dysfunction.
There are no studies evaluating the microcirculation of patients with the cardiac form of
Chagas disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01722942 -
Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death
|
N/A | |
| Recruiting |
NCT04239144 -
Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease
|
N/A | |
| Recruiting |
NCT05519046 -
Cardiac Contractility Modulation in Chagas Heart Disease
|
N/A | |
| Recruiting |
NCT04853758 -
Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
|
Phase 3 | |
| Completed |
NCT02516293 -
Cardiac Rehabilitation in Chagas Heart Failure
|
Phase 2/Phase 3 | |
| Completed |
NCT01557140 -
A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
|
Phase 4 | |
| Completed |
NCT02517632 -
Physical Exercise Program in Chronic Chagas Heart Disease
|
Phase 3 | |
| Recruiting |
NCT02099903 -
Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease
|
N/A | |
| Completed |
NCT01863576 -
Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy
|
Phase 0 | |
| Completed |
NCT01340963 -
The Signal-averaged ElectrocArdiogram in Long Term Follow-up of Chronic CHagas Disease - RIO de Janeiro Cohort
|
N/A | |
| Recruiting |
NCT03193749 -
A Trial Testing Amiodarone in Chagas Cardiomiopathy
|
Phase 3 | |
| Completed |
NCT00323973 -
Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity
|
Phase 3 | |
| Completed |
NCT04090489 -
Congenital Chagas Disease: Long Term Follow up of Treated Children. Preliminary Report or Cardiological Evaluation in Chagas Disease Treated Children
|
||
| Terminated |
NCT00349271 -
Cell Therapy in Chagas Cardiomyopathy
|
Phase 3 |